Press Releases

Date Title and Summary View
Apr 02, 2018
MacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ROCKVILLE, MD , April 02, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the closing of its previously

Mar 28, 2018
MacroGenics Announces Pricing of Public Offering of Common Stock

ROCKVILLE, MD , March 28, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the pricing of an underwritten public

Mar 26, 2018
MacroGenics Announces Proposed Public Offering of Common Stock

ROCKVILLE, MD , March 26, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has commenced an underwritten

Mar 09, 2018
MacroGenics to Present at Cowen Health Care Conference
Rockville, MD, March 09, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Additional Formats
Feb 27, 2018
MacroGenics Provides Update on Corporate Progress and 2017 Financial Results
ROCKVILLE, Md., Feb. 27, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided a corporate progress update and reported
Additional Formats
Feb 14, 2018
MacroGenics Announces Date of Fourth Quarter and Full Year 2017 Financial Results Conference Call
ROCKVILLE, MD, Feb. 14, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that on Tuesday, February 27, 2018, the
Additional Formats
Feb 06, 2018
MacroGenics to Participate in Two Upcoming Investor Conferences
ROCKVILLE, MD, Feb. 06, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Additional Formats
Jan 23, 2018
MacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis
FDA grants Fast Track designation to margetuximab for treatment of metastatic breast cancer
Additional Formats
Jan 18, 2018
Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at 2018 ASCO Gastrointestinal Cancers Symposium
Chemotherapy-free, immunotherapeutic combination evaluated 32% Overall response rate in second-line gastric cancer patients Well tolerated in dose escalation and expansion cohorts Rockville, MD, Jan. 18, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical
Additional Formats
Jan 04, 2018
MacroGenics to Present at the 36th Annual J.P. Morgan Healthcare Conference
ROCKVILLE, MD, Jan. 04, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Jan 04, 2018
MacroGenics Enters Research Collaboration with Roche to Develop a Novel Bispecific Molecule
ROCKVILLE, MD, Jan. 04, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious
Additional Formats
Dec 11, 2017
Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART® Molecule, Presented at 59th Annual ASH Meeting
Encouraging initial anti-leukemic activity with durable responses and acceptable tolerability observed in dose expansion cohort Data supports combination with MGA012 (anti-PD-1) to potentially enhance anti-leukemic effects Rockville, MD, Dec. 11, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc.
Additional Formats
Dec 05, 2017
MacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with Incyte
ROCKVILLE, MD, Dec. 05, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Nov 15, 2017
MacroGenics Names Dr. Jay Siegel to its Board of Directors
ROCKVILLE, MD, Nov. 15, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Nov 13, 2017
MacroGenics to Participate in Two Upcoming Investor Conferences
ROCKVILLE, MD, Nov. 13, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Nov 10, 2017
MacroGenics Announces Poster Presentations at 32nd Annual SITC Meeting 2017
ROCKVILLE, Maryland, Nov. 10, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Nov 08, 2017
MacroGenics Provides Update on Corporate Progress and Third Quarter 2017 Financial Results
ROCKVILLE, Md., Nov. 08, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Nov 01, 2017
MacroGenics Announces Date of Third Quarter 2017 Financial Results Conference Call
ROCKVILLE, MD, Nov. 01, 2017 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 8, 2017, the Company will release its financial results for the quarter ended September 30, 2017. The Company's management team will host a conference call discussing the
Additional Formats
Nov 01, 2017
MacroGenics to Present Phase 1 Data on Flotetuzumab, a CD123 x CD3 DART® Molecule, at 59th Annual ASH Meeting
ROCKVILLE, MD, Nov. 01, 2017 (GLOBE NEWSWIRE) -- — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Oct 25, 2017
Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012
  Incyte gains exclusive, worldwide development and commercialization rights to MGA012 in all indications MacroGenics to receive an upfront cash payment of $150 million plus potential milestone payments and royalties, and retains right to develop its pipeline assets in combination with MGA012
Additional Formats
Sep 10, 2017
Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART® Molecule, Presented at ESMO Congress 2017
Acceptable tolerability observed in first-in-human study Encouraging initial anti-leukemic activity observed in relapsed/refractory AML patients ROCKVILLE, MD, Sept. 10, 2017 (GLOBE NEWSWIRE) -- --  MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering
Additional Formats
Sep 05, 2017
MacroGenics Advances Two First-in-Class Clinical DART® Molecules
First patient dosed with MGD013 (PD-1 x LAG-3 DART) IND submitted for MGD014 (HIV x CD3 DART) NIAID exercises option to advance MGD014 and develop second HIV-directed DART molecule ROCKVILLE, MD , Sept. 05, 2017 (GLOBE NEWSWIRE) --   MacroGenics, Inc.
Additional Formats
Aug 31, 2017
MacroGenics Announces Termination of Duvortuxizumab Collaboration and License Agreement with Janssen

Development of MGD015 (JNJ-9383) to continue by Janssen

Additional Formats
Aug 30, 2017
MacroGenics to Participate in Three Investor Conferences in September
ROCKVILLE, MD, Aug. 30, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Aug 09, 2017
MacroGenics to Present at the Wedbush PacGrow Healthcare Conference
ROCKVILLE, MD, Aug. 09, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats